State Street Corp lessened its holdings in Iradimed Corporation (NASDAQ:IRMD – Free Report) by 2.0% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 165,533 shares of the medical equipment provider’s stock after selling 3,383 shares during the quarter. State Street Corp’s holdings in Iradimed were worth $8,325,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also made changes to their positions in the business. Stifel Financial Corp increased its position in Iradimed by 9.8% during the 3rd quarter. Stifel Financial Corp now owns 24,428 shares of the medical equipment provider’s stock valued at $1,229,000 after buying an additional 2,174 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its position in shares of Iradimed by 1.9% during the third quarter. Jacobs Levy Equity Management Inc. now owns 24,779 shares of the medical equipment provider’s stock valued at $1,246,000 after acquiring an additional 472 shares in the last quarter. Walleye Capital LLC purchased a new position in Iradimed in the 3rd quarter worth approximately $361,000. Martingale Asset Management L P lifted its position in Iradimed by 15.4% in the 3rd quarter. Martingale Asset Management L P now owns 12,529 shares of the medical equipment provider’s stock valued at $630,000 after acquiring an additional 1,671 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Iradimed during the 3rd quarter valued at $250,000. Institutional investors own 92.34% of the company’s stock.
Insider Buying and Selling
In other Iradimed news, CFO John Glenn sold 2,500 shares of the stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $54.18, for a total value of $135,450.00. Following the transaction, the chief financial officer now owns 4,383 shares of the company’s stock, valued at approximately $237,470.94. This represents a 36.32 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 37.10% of the stock is currently owned by corporate insiders.
Iradimed Price Performance
Iradimed Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Monday, November 25th. Investors of record on Friday, November 15th were given a dividend of $0.15 per share. The ex-dividend date was Friday, November 15th. This represents a $0.60 dividend on an annualized basis and a yield of 1.10%. Iradimed’s dividend payout ratio (DPR) is 41.10%.
Iradimed Company Profile
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.
Recommended Stories
- Five stocks we like better than Iradimed
- What Are the FAANG Stocks and Are They Good Investments?
- S&P 500 ETFs: Expense Ratios That Can Boost Your Long-Term Gains
- How to Capture the Benefits of Dividend Increases
- How AI Implementation Could Help MongoDB Roar Back in 2025
- How to Invest in the FAANG Stocks
- Hedge Funds Boost Oil Positions: Is a Major Rally on the Horizon?
Want to see what other hedge funds are holding IRMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iradimed Corporation (NASDAQ:IRMD – Free Report).
Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.